nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-6-135-141nnp-2150Research ArticleREVIEWSОБЗОРЫNeuromyelitis optica spectrum disorders and complement system: issues of pathogenesis and therapeutic optionsЗаболевания спектра оптиконевромиелита и система комплемента: вопросы патогенеза и терапевтические возможностиhttps://orcid.org/0000-0002-9769-447XКрасновВ. С.KrasnovV. S.

Владимир Сергеевич Краснов

197022, Санкт-Петербург, ул. Льва Толстого, 6–8

Vladimir Sergeevich Krasnov

6-8, L’va Tolstogo St., St. Petersburg 197022

krasnov_volod@mail.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава РоссииРоссияAcad. I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of RussiaRussian Federation202317122023156135141Copyright © Krasnov V.S., 20232023Краснов В.С.Krasnov V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2150

An important component of the pathogenesis of neuromyelitis optica spectrum diseases (NMOSD) with antibodies to aquaporin-4 (AQP4-IgG) is a classical pathway of complement system (CS) activation with the implementation of mechanisms of complement-mediated cytotoxicity. Eculizumab is a humanized monoclonal antibody that suppresses the final stage of CS activation and has a high affinity for its C5 component. The most important components in the pathogenesis of NMOSD with AQP4-IgG, the role of CS, the results of clinical trials with the drug eculizumab and its place in the treatment of NMOSD are discussed.

Важным звеном патогенеза заболеваний спектра оптиконевромиелита (ЗСОНМ) с антителами к аквапорину-4 (AQP4-IgG) является повышение активности системы комплемента (СК) по классическому пути с реализацией механизмов комплемент-опосредованной цитотоксичности. Экулизумаб – гуманизированное моноклональное антитело, которое подавляет терминальную стадию активации СК, обладая высокой аффинностью к ее С5-компоненту. Обсуждаются основные звенья патогенеза ЗСОНМ с AQP4IgG, роль в нем СК, результаты клинических исследований препарата экулизумаб, а также его место в терапии ЗСОНМ.

заболевание спектра оптиконевромиелитасистема комплемента: экулизумабneuromyelitis optica spectrum diseasecomplement system: eculizumabСтатья спонсируется компанией «Генериум»This article has been supported by GeneriumReferencesBruscolini A, Sacchetti M, La Cava M, et al. Diagnosis and management of neuromyelitis optica spectrum disorders – An update. Autoimmun Rev. 2018 Mar;17(3):195-200. doi: 10.1016/j.autrev.2018.01.001. Epub 2018 Jan 13.Bruscolini A, Sacchetti M, La Cava M, et al. Diagnosis and management of neuromyelitis optica spectrum disorders – An update. Autoimmun Rev. 2018 Mar;17(3):195-200. doi: 10.1016/j.autrev.2018.01.001. Epub 2018 Jan 13.Краснов ВС, Бахтиярова КЗ, Евдошенко ЕП и др. Консенсусное мнение по ведению пациентов с заболеваниями спектра оптиконевромиелита: вопросы терминологии и терапии. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):139-48. doi: 10.14412/2074-27112022-6-139-148Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139-48. doi: 10.14412/2074-2711-2022-6-139-148 (In Russ.)].Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79. doi: 10.1016/j.mayocp.2016.12.014Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017 Apr;92(4):663-79. doi: 10.1016/j.mayocp.2016.12.014Whittam D, Wilson M, Hamid S, et al. What’s new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017 Nov;264(11):2330-4. doi: 10.1007/s00415-0178445-8Whittam D, Wilson M, Hamid S, et al. What’s new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017 Nov;264(11):2330-4. doi: 10.1007/s00415-0178445-8Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729Lucchinetti СF, Guo Y, Popescu BFG, et al. The Pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica Brain Pathol. 2014 Jan;24(1):83-97. doi: 10.1111/bpa.12099Lucchinetti СF, Guo Y, Popescu BFG, et al. The Pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica Brain Pathol. 2014 Jan;24(1):83-97. doi: 10.1111/bpa.12099Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013 Sep;36:159-71. doi: 10.1016/j.preteyeres.2013.03.001Levin MH, Bennett JL, Verkman AS. Optic neuritis in neuromyelitis optica. Prog Retin Eye Res. 2013 Sep;36:159-71. doi: 10.1016/j.preteyeres.2013.03.001Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019 Jan;27:412-8. doi: 10.1016/j.msard.2018.12.002Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019 Jan;27:412-8. doi: 10.1016/j.msard.2018.12.002Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther. 2021 Aug;21(8):1073-86. doi: 10.1080/14712598.2021.1884223Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther. 2021 Aug;21(8):1073-86. doi: 10.1080/14712598.2021.1884223Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:87592. doi: 10.1007/s00401-020-02132-yHöftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139:87592. doi: 10.1007/s00401-020-02132-yTakai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143:1431-46. doi: 10.1093/brain/awaa102Takai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143:1431-46. doi: 10.1093/brain/awaa102Nakashima I. Is MOG-IgG another biomarker for neuromyelitis optica? J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):807. doi: 10.1136/jnnp-2017-316247Nakashima I. Is MOG-IgG another biomarker for neuromyelitis optica? J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):807. doi: 10.1136/jnnp-2017-316247Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017 Oct;264(10):2088-94. doi: 10.1007/s00415-017-8596-7Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017 Oct;264(10):2088-94. doi: 10.1007/s00415-017-8596-7Contentti EC, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428. doi: 10.1016/j.msard.2020.102428Contentti EC, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord. 2020 Oct;45:102428. doi: 10.1016/j.msard.2020.102428Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and longterm management. J Neurol. 2023 Jul;270(7):3341-68. doi: 10.1007/s00415-02311634-0Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and longterm management. J Neurol. 2023 Jul;270(7):3341-68. doi: 10.1007/s00415-02311634-0Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013 Apr;14(4):265-77. doi: 10.1038/nrn3468Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013 Apr;14(4):265-77. doi: 10.1038/nrn3468Симанив ТО, Краснов ВС, Касаткин ДС. Оптиконевромиелит в фокусе. Практическое руководство в схемах и таблицах. Москва: Практическая медицина; 2023. 176 с.Simaniv TO, Krasnov VS, Kasatkin DS. Optikonevromielit v fokuse. Prakticheskoe rukovodstvo v skhemakh i tablitsakh [Opticoneuromyelitis in focus. Practical guidance in diagrams and tables]. Moscow: Prakticheskaya meditsina; 2023. 176 p. (In Russ.)].Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013 Oct;93(4):1543-62. doi: 10.1152/physrev.00011.2013Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013 Oct;93(4):1543-62. doi: 10.1152/physrev.00011.2013Hinson SR, Romero MF, Popescu BFG, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci. 2011;109(4):1245-50. doi: 10.1073/pnas.1109980108. Epub 2011 Nov 29.Hinson SR, Romero MF, Popescu BFG, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci. 2011;109(4):1245-50. doi: 10.1073/pnas.1109980108. Epub 2011 Nov 29.Day RE, Kitchen P, Owen DS, et al. Human aquaporins: regulators of transcellular water flow. Biochim Biophys Acta. 2014 May;1840(5):1492-506. doi: 10.1016/j.bbagen.2013.09.033Day RE, Kitchen P, Owen DS, et al. Human aquaporins: regulators of transcellular water flow. Biochim Biophys Acta. 2014 May;1840(5):1492-506. doi: 10.1016/j.bbagen.2013.09.033Saadoun S, Papadopoulos M. Role of membrane complement regulators in neuromyelitis optica. Mult Scler J. 2015;21(13):1644-54. doi: 10.1177/1352458515571446Saadoun S, Papadopoulos M. Role of membrane complement regulators in neuromyelitis optica. Mult Scler J. 2015;21(13):1644-54. doi: 10.1177/1352458515571446Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler J. 2012;18(1):510. doi: 10.1177/1352458511431077Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler J. 2012;18(1):510. doi: 10.1177/1352458511431077Wang Y, Zhu M, Liu C. Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis. Front Neurol. 2018 Aug 7;9:648. doi: 10.3389/fneur.2018.00648Wang Y, Zhu M, Liu C. Blood Brain Barrier Permeability Could Be a Biomarker to Predict Severity of Neuromyelitis Optica Spectrum Disorders: A Retrospective Analysis. Front Neurol. 2018 Aug 7;9:648. doi: 10.3389/fneur.2018.00648Краснов ВС, Макшаков ГС, Калинин ИВ и др. Коморбидность заболевания спектра оптиконейромиелита и системной красной волчанки. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(7):102-8. doi: 10.17116/jnevro2020120071102Krasnov VS, Makshakov GS, Kalinin IV, et al. Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):102-8. doi: 10.17116/jnevro2020120071102 (In Russ.).Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. Mult Scler Relat Disord. 2021 Nov;56:103227. doi: 10.1016/j.msard.2021.103227Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. Mult Scler Relat Disord. 2021 Nov;56:103227. doi: 10.1016/j.msard.2021.103227Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433-59. doi: 10.1146/annurev-immunol-032713-120154Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433-59. doi: 10.1146/annurev-immunol-032713-120154Pettigrew HD, Teuber SS, Gershwin ME. Clinical Significance of Complement Deficiencies. Ann N Y Acad Sci. 2009;1173(1):108-23. doi: 10.1111/j.17496632.2009.04633.xPettigrew HD, Teuber SS, Gershwin ME. Clinical Significance of Complement Deficiencies. Ann N Y Acad Sci. 2009;1173(1):108-23. doi: 10.1111/j.17496632.2009.04633.xШахиджанов СС, Филиппова АЕ, Бутылин АА, Атауллаханов ФИ. Патологии системы комплемента. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019;18(3):130-44. doi:10.24287/17261708-2019-18-3-130-144Shakhidzhanov SS, Filippova AE, Butilin AA, Ataullakhanov FI. Pathologies of the complement system. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2019;18(3):130-44. doi: 10.24287/1726-1708-2019-18-3-130-144 (In Russ.).Nytrova P, Potlukova E, Kemlink D, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014 Sep 15;274(1-2):185-91. doi: 10.1016/j.jneuroim.2014.07.001Nytrova P, Potlukova E, Kemlink D, et al. Complement activation in patients with neuromyelitis optica. J Neuroimmunol. 2014 Sep 15;274(1-2):185-91. doi: 10.1016/j.jneuroim.2014.07.001Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport. 2009 Mar 25;20(5):508-12. doi: 10.1097/wnr.0b013e32832776f4Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport. 2009 Mar 25;20(5):508-12. doi: 10.1097/wnr.0b013e32832776f4Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007 Dec 11;69(24):2221-31. doi: 10.1212/01.WNL.0000289761.64862.ceHinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007 Dec 11;69(24):2221-31. doi: 10.1212/01.WNL.0000289761.64862.ceZhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011 12;70(6):943-54. doi: 10.1002/ana.22551Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011 12;70(6):943-54. doi: 10.1002/ana.22551Chen T, Lennon VA, Liu YU, et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest. 2020;130(8):4025-38. doi: 10.1172/JCI134816Chen T, Lennon VA, Liu YU, et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest. 2020;130(8):4025-38. doi: 10.1172/JCI134816Tradtrantip L, Yao X, Su T, et al. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017 Jul;134(1):35-44. doi: 10.1007/s00401-017-1734-6Tradtrantip L, Yao X, Su T, et al. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017 Jul;134(1):35-44. doi: 10.1007/s00401-017-1734-6Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2018 Oct 22;15(1):294. doi: 10.1186/s12974-018-1333-zDuan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2018 Oct 22;15(1):294. doi: 10.1186/s12974-018-1333-zDuan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun. 2019 Jul 11;7(1):112. doi: 10.1186/s40478-019-0766-7Duan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun. 2019 Jul 11;7(1):112. doi: 10.1186/s40478-019-0766-7Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi: 10.1016/S1474-4422(20)30392-6Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-7. doi: 10.1016/S1474-4422(20)30392-6Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866Wingerchuk DM, Fujihara K, Palace J, et al. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021 Jun;89(6):1088-98. doi: 10.1002/ana.26049Wingerchuk DM, Fujihara K, Palace J, et al. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021 Jun;89(6):1088-98. doi: 10.1002/ana.26049Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021 Jan;47:102641. doi: 10.1016/j.msard.2020.102641Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021 Jan;47:102641. doi: 10.1016/j.msard.2020.102641Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler J. 2022;28(3):480-6. doi: 10.1177/13524585211038291Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler J. 2022;28(3):480-6. doi: 10.1177/13524585211038291Hemmer B. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-opticaSpektrum-Erkrankungen und MOG-IgGassoziierten Erkrankungen, S2k-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Available from: www.dgn.org/leitlinienHemmer B. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-opticaSpektrum-Erkrankungen und MOG-IgGassoziierten Erkrankungen, S2k-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Available from: www.dgn.org/leitlinienShosha E, Aljarallah SA, Fugham NA, et al. Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2022 Oct;66:104062. doi: 10.1016/j.msard.2022.104062Shosha E, Aljarallah SA, Fugham NA, et al. Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2022 Oct;66:104062. doi: 10.1016/j.msard.2022.104062Chatterton S, Parratt JDE, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report. Front Neurol. 2022 Aug 8;13:951423. doi: 10.3389/fneur.2022.951423Chatterton S, Parratt JDE, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report. Front Neurol. 2022 Aug 8;13:951423. doi: 10.3389/fneur.2022.951423Mao-Draayer Y, Thiel S, Mills EA, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020 Mar;16(3):154-70. doi: 10.1038/s41582-020-0313-y. Epub 2020 Feb 20.Mao-Draayer Y, Thiel S, Mills EA, et al. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020 Mar;16(3):154-70. doi: 10.1038/s41582-020-0313-y. Epub 2020 Feb 20.

The authors declare that there are no conflicts of interest present.